Moderna, Inc. (MRNA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $47.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 18%; Below-average business quality; Rich valuation.
Moderna is an mRNA medicine company with three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (RSV vaccine for adults). Total revenue was $1.9 billion in 2025, largely from COVID vaccine sales, while the pipeline of 35 programs spans infectious disease,... Read more
Sell if holding. Engine safety override at $47.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 18%; Below-average business quality; Rich valuation. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 4.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Moderna, Inc.
Latest news
- U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will C — benzinga May 18, 2026 neutral
- Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb — benzinga May 11, 2026 positive
- Moderna Shares Surge On Hantavirus Concerns: What Investors Need To Know — benzinga May 11, 2026 positive
- Stock Market Today: Dow, Nasdaq Futures Fall As Trump Rejects 'Totally Unacceptable' Iran Peace Proposal—Micron, Moderna — benzinga May 11, 2026 negative
- Why Digi Power X Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket — benzinga May 11, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCOVID vaccines10-K Item 1: 'In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $47.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 18%; Below-average business quality; Rich valuation. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $44.74. Score 4.3/10, moderate confidence.
Take-profit target: $58.29 (+21.2% upside). Prior stop was $44.74. Stop-loss: $44.74.
Concentration risk — Product: COVID vaccines; Target reached (-18.9% upside); Quality below floor (3.1 < 4.0).
Moderna, Inc. trades at a P/E of N/A (forward -11.6). TrendMatrix value score: 3.6/10. Verdict: Sell.
30 analysts cover MRNA with a consensus score of 3.2/5. Average price target: $43.
What does Moderna, Inc. do?Moderna is an mRNA medicine company with three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA...
Moderna is an mRNA medicine company with three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (RSV vaccine for adults). Total revenue was $1.9 billion in 2025, largely from COVID vaccine sales, while the pipeline of 35 programs spans infectious disease, oncology, and rare disease.